TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02462096

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ReLeaf
Description: The ReLeaf catheter is expected to enable a physician to create tissue leaflets that, in turn, generate a valve effect in the deep veins of the legs.
Study: NCT03053167

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Irinotecan: 180mg/㎡+NS250ml, ivgtt, 90min, d1 Every 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Raltitrexed
Description: Raltitrexed: 3mg/㎡+NS100ml，ivgtt，15min, d1 Every 3 weeks
Study: NCT01734603

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: experimental rehabilitation program
Description: Duration training = 40 min : 5 cycles of 6 min each Week 1 speed of the walking exercise fixed at 70% of the max walking test's speed done on the initial walking test speed of the walking recovery fixed at 40% Walking slope : 0% Increase of the speed = 0.1 km/h after each training without pain.~* Week 2 Walking speed = average of the walking speeds done on week 1 Walking slope = 1% Recovery slope = 0% Increase of the slope = 0.5% after each training without pain.~* Week 3 Walking speed = 70% of the maximal walking test's speed Recovery speed = 40 % of the maximal walking test's speed Slope = average of the slopes done on week 2 Increase of the speed = 0.1 km/h .~* Week 4 Speeds = average of the walking speeds done on week 3 Walking slope = 1% Recovery slope = 0% Increase of the slope is 0.5% .

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: conventional rehabilitation program
Description: Duration of the training 40 minutes (time excluding rest and warm up)~Initial intensity = 3.2 km per hour and slope at 0% Walking until pain 3/5, then stop until pain completely subsides.Resume of walking as soon as possible.~Increase :~Week 1: if the walking is possible during 8 minutes, increase of the slope of 0.5% in each training until 10% Week 2 :if the walking is possible during 8 minutes, increase of the speed 0.2 mile per hour until 3 mph Week 3 :if the walking is possible during 8 minutes, increase of the slope 2% at each training until 15% Week 4 : if the walking is possible during 8 minutes, increase the speed 0.2mph at each training as long as it is possible.
Study: NCT00804908

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: temozolomide
Description: temozolomide capsule administered orally once daily for 5 days every 28 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: temozolomide
Description: temozolomide capsule administered orally once daily for 5 days every 28 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: temozolomide
Description: temozolomide capsule administered orally once daily for 5 days every 28 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ABT-888
Description: ABT-888 capsule administered orally twice daily for 7 days every 28 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ABT-888
Description: ABT-888 capsule administered orally twice daily for 7 days every 28 days

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for ABT-888 capsule administered orally twice daily for 7 days every 28 days
Study: NCT01955330

Intervention type: PROCEDURE
Intervention: Robotic Hybrid coronary artery revascularization
Description: Lita to LAD performed by robot, Hybrid stent to other diseased coronary artery
Study: NCT04550429

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: MyoSure Hysteroscopic Morcellator Device
Description: This device is normally used for this procedure, but I included it as intervention because we will lower the pressure for one arm of the study (treatment) and keep the pressure in the other arm (control) as the standard of care.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: MyoSure Hysteroscopic Morcellator Device
Description: This device is normally used for this procedure, but I included it as intervention because we will lower the pressure for one arm of the study (treatment) and keep the pressure in the other arm (control) as the standard of care.
Study: NCT06156748

Intervention type: PROCEDURE
Intervention: postoperative adjuvant transarterial chemoembolization
Description: HCC patients received hepatectomy and PA-TACE.
Study: NCT02724618

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Curcumin
Description: 120mg/d oral nanocurcumin (3 capsules of SinaCurcumin®40 per day) 3 days before and during radiotherapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: RT
Description: EBRT is delivered as Intensity-Modulated Radiation Therapy (IMRT) or 3D-conformal RT

Intervention type: RADIATION
Group type: PLACEBO_COMPARATOR
Intervention: RT
Description: EBRT is delivered as Intensity-Modulated Radiation Therapy (IMRT) or 3D-conformal RT

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (3 placebo capsules of SinaCurcumin®40 per day), 3 days before and during radiotherapy
Study: NCT02433808

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neostigmine Group
Description: Neostigmine will be used to reverse neuromuscular block at the conclusion of the surgical procedure. The effect on muscle strength will be determined using the TOF-Watch-SX and clinical examination

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: No Neostigmine group
Description: Saline will be administered to patients at the end of the surgical procedure when neuromuscular function has recovered
Study: NCT05467969

Intervention type: BEHAVIORAL
Intervention: Teleteaching of procedural skills through the online multiscreen display teleconference platform
Description: Teleteaching of procedural skills include three different techniques through three different workshops. Each of the workshops was delivered by a respected expert faculty and then accompanied by skills assessment subsequently. Three different group of learners joined the workshops on knotting skills, suturing skills and laparoscopic hand-eye coordination skills respectively.
Study: NCT04228380

Intervention type: OTHER
Intervention: No intervention
Description: No intervention

Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study: NCT05795608

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: respiratory exercise with incentive spirometry
Description: Subjects in the intervention group were trained to perform 15 minutes of respiratory exercise with incentive spirometry four times a day for two days before surgery by trained medical personnel. First, subjects were instructed to make a good seal over the incentive spirometry mouthpiece with their lips. Afterward, they were asked to inhale deeply and slowly, and they were also directed to hold their breath at the end of inspiration
Study: NCT03762993

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Vocal rest and Controlled Phonation
Description: Voice rest and semi occluded vocal tract voice exercises

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Vocal rest and Controlled Phonation
Description: Voice rest and semi occluded vocal tract voice exercises
Study: NCT05002712

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Heavy resistance training
Description: Their training program included 4 resistance exercises with heavy weight lifting of the leg muscles. 3 sets of 6-8 repetitions of 80-90 % of maximal load were performed with a barbell squat (range of 0 to 90º knee flexion), lying leg curl, seated calf raises, and leg extension. The rests between the sets and the exercises lasted 5 minutes.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Contrast strength training
Description: Their resistance training program contained the same exercises as the high resistance training group, but with different intensity. Athlete performed each exercise for the first time with 5-7 reps with 80 % of the 1RM load followed by 15-20 reps with 40 % of the maximal load to complete the 3 sets for each exercise. The rest period between series was 60 seconds and the rest period between exercises was 5 minutes. For example, 5 heavy barbell squats followed immediately by 20 squat with lighter weight to complete 3 sets.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Elastic resistance training
Description: During the intervention, the group conducted a 'elastic resistance training' with the same muscle groups. External resistance was provided by blue thera-band latex-free exercise bands in this training. Each exercise was performed three times for a total of 15-25 repetitions. In between sets, a 5-minute rest period was given and there was a 25-second rest period in between exercise performance. The intensity of each exercise was increased with the black thera band at the midpoint (start of week 7) of the training. The following figure shows the resistance of the blue and black bands to 100 percent elongation. Following figure shows the resistance offered by blue and black band at 100% elongation.
Study: NCT00404144

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Drug Eluting Balloon
Description: PCI of small vessels single arm study
Study: NCT02564003

Intervention type: DRUG
Intervention: Oxycodone
Description: oxycodone 0,1 mg/kg iv
Study: NCT03819114

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levonorgestrel (LNG)
Description: LNG tablet(s) were administered by mouth in a directly observed manner.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levonorgestrel (LNG)
Description: LNG tablet(s) were administered by mouth in a directly observed manner.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levonorgestrel (LNG)
Description: LNG tablet(s) were administered by mouth in a directly observed manner.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levonorgestrel (LNG)
Description: LNG tablet(s) were administered by mouth in a directly observed manner.
Study: NCT02572102

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Energy Drink
Description: Energy Drink, two 16oz containers consumed in 45 minutes

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Panax Ginseng
Description: Panax Ginseng, lime juice, water and cherry flavoring

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Lime juice, water and cherry flavoring
Study: NCT01263847

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Galactooligosaccharide
Description: Zero, 5 or 10 g/day of galactooligosaccharide will be administered in two yogurt drinks containing about 300 mg total calcium each per day for three weeks. During a clinical visit following three weeks of consumption, zero, 2.5 or 5 g of galactooligosaccharide will be administered in the same yogurt with the addition of 15 mg Ca-44 (calcium chloride). Participants will be given one of the above yogurts at breakfast in addition to intravenously receiving 3.5 mg Ca-43 (calcium chloride) in 4 ml saline one hour after breakfast consumption.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Galactooligosaccharide
Description: Zero, 5 or 10 g/day of galactooligosaccharide will be administered in two yogurt drinks containing about 300 mg total calcium each per day for three weeks. During a clinical visit following three weeks of consumption, zero, 2.5 or 5 g of galactooligosaccharide will be administered in the same yogurt with the addition of 15 mg Ca-44 (calcium chloride). Participants will be given one of the above yogurts at breakfast in addition to intravenously receiving 3.5 mg Ca-43 (calcium chloride) in 4 ml saline one hour after breakfast consumption.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Galactooligosaccharide
Description: Zero, 5 or 10 g/day of galactooligosaccharide will be administered in two yogurt drinks containing about 300 mg total calcium each per day for three weeks. During a clinical visit following three weeks of consumption, zero, 2.5 or 5 g of galactooligosaccharide will be administered in the same yogurt with the addition of 15 mg Ca-44 (calcium chloride). Participants will be given one of the above yogurts at breakfast in addition to intravenously receiving 3.5 mg Ca-43 (calcium chloride) in 4 ml saline one hour after breakfast consumption.
Study: NCT03531346

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Daily-disposable soft contact lens
Description: Subjects were refitted with Silicone-Hydrogel (Delefilcon A) or Hydrogel (Omafilcon A) daily-disposable soft contact lenses based on their fit, reported comfort and tear film surface quality.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Daily-disposable soft contact lens
Description: Subjects were refitted with Silicone-Hydrogel (Delefilcon A) or Hydrogel (Omafilcon A) daily-disposable soft contact lenses based on their fit, reported comfort and tear film surface quality.
Study: NCT03900091

Intervention type: DIAGNOSTIC_TEST
Intervention: Multiplex PCR assay for meningitis
Description: CSF from cases to be analysed with a FilmArray ME Panel

Intervention type: DIAGNOSTIC_TEST
Intervention: Multiplex vertical flow microarrray assay for meningitis
Description: CSF from cases will also undergo analysis with a newly developed prototype for point-of-care diagnostic tool for CNS infections identification. The tool is a DNA-based vertical flow microarray technology printed on paper.

Intervention type: DIAGNOSTIC_TEST
Intervention: Profiling of blood proteins by multi-analyte Profiling technology
Description: Blood from cases and controls to be analysed using Luminex technology to identify protein profiles associated with severe and non-severe infection. Myxovirus protein A (MxA) will also be analysed by the Luminex assay, to associate MxA levels with severe/non-severe infection.

Intervention type: DIAGNOSTIC_TEST
Intervention: Profiling of blood proteins by multi-analyte Profiling technology
Description: Blood from cases and controls to be analysed using Luminex technology to identify protein profiles associated with severe and non-severe infection. Myxovirus protein A (MxA) will also be analysed by the Luminex assay, to associate MxA levels with severe/non-severe infection.

Intervention type: OTHER
Intervention: Typing and whole genome sequencing
Description: Pathogenic strains isolated from nasopharyngeal swabs from cases and controls will undergo whole genome sequencing (WGS) and typing .

Intervention type: OTHER
Intervention: Typing and whole genome sequencing
Description: Pathogenic strains isolated from nasopharyngeal swabs from cases and controls will undergo whole genome sequencing (WGS) and typing .
Study: NCT02026531

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 3-Helium gas
Description: 3-Helium gas for MRI contrast
Study: NCT00248040

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reparixin continuous infusion
Description: The Investigational Product was administered as an intravenous infusion into a (high flow) central vein or through an arterio-venous fistula, by an infusion pump adequate to provide reliable infusion rates, as per treatment schedule. Total infusion volume did not exceed 500 mL/24 hours. A dose of 2.772 mg/kg body weight/hour was to be administered for 12 hours. Placebo was volume/schedule matched saline.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: reparixin intermittent infusion
Description: A dose of 2.244 mg/kg body weight was to be administered over a 30-minute period, followed by a 1.5-hour interval. Twelve doses were to be administered over a total period of 22.5 hours. Placebo was volume/schedule matched saline.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo infusion
Description: placebo was volume/schedule matched saline
Study: NCT03221153

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Simulation techique
Description: The intervention group will be in a simulated case with mock scenarios and interaction by 'acting out' the clinical situation where knowledge and attitudes about safety in hospitalized patients will be assessed.
Study: NCT01715324

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adjuvant Growth Hormon
Description: The treatment group will receive 2.5 mg of Saizen daily via subcutaneous injections, from the beginning of the ovarian reserve stimulation until the day of the ovulation triggering
Study: NCT04683614

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Norepinephrine
Description: 5 mic/kg/hr norepinephrine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fresh frozen plasma
Description: early administration of fresh frozen plasma
Study: NCT00426413

Intervention type: DRUG
Intervention: pioglitazone
Description: Obese AA subjects with DKA or severe hyperglycemia that are able to discontinue insulin at 12 weeks or less will be randomized (blinded fashion) to receive either placebo or pioglitazone qd. The subjects will be followed while in the study arm and beta-cell function will be assessed using OGTT at set intervals.
Study: NCT00543413

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK8141
Description: MK8141 250 mg tablet once daily; 500 mg tablet once daily 4 week treatment period

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK8141
Description: MK8141 250 mg tablet once daily; 500 mg tablet once daily 4 week treatment period

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Comparator: placebo (unspecified)
Description: MK8141 Pbo tablet once daily. 4 week treatment period.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enalapril
Description: Enalapril 20 mg tablet once daily. 4 week treatment period.
Study: NCT01748513

Intervention type: OTHER
Intervention: preoperative venous return optimizing
Description: Preoperative transthoracic echocardiography (TTE) was performed in the awake state before and after volume challenge based on 6ml colloids /kg ideal body weight.
Study: NCT02844309

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thalidomide
Description: thalidomide 50-150 mg per night
Study: NCT03403283

Intervention type: OTHER
Intervention: 15 subjects with Non Proliferative Diabetic Retinopathy(mild, moderate and severe). 15 subjects with Proliferative Diabetic Retinopathy

Intervention type: OTHER
Intervention: Healthy Controls 15 age matched control subjects
Study: NCT02217358

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NBI endoscopy
Description: see in detail description of the study part of the protocol
Study: NCT01565824

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: web-based support
Study: NCT03931369

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tolvaptan 15 MG
Description: Single administration of one pill of 15 MG tolvaptan
Study: NCT00851058

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief group counseling
Description: Four group counseling sessions and six hours of direct observations of the emergency and trauma services in a busy urban hospital.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Community Counseling
Description: Four session of group counseling and six hours of guided observation of the emergency and trauma services at a busy urban hospital

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Prototypic community service
Description: Two educational session on road safety and 16 hours of volunteering in a local not for profit community service.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Prototypic community service
Description: Four hours education about road safety and 16 hours volunteering at a local not for profit community service
Study: NCT04043858

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midodrine 2.5 mg tab
Description: Patients receive an oral daily dose of 2.5 mg midodrine if age 7-12 years and receive 2.5 mg twice daily of more than 12 years
Study: NCT03323424

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Systemic treatment + Stereotactic Body Radio-Therapy (SBRT)
Description: According to the usual practice, patients will receive their systemic treatment, composed of :~* Taxane + trastuzumab +pertuzumab for metastatic breast cancers;~* FOLFOX or FOLFIRI + cetuximab for metastatic colorectal cancers;~* 5FU-Platine + cetuximab for metastatic head and neck cancers; for six cycles and a maintenance of the targeted therapy until progression or unacceptable toxicity.~If progression occurs before the 6th cycles, patients could receive a different line of treatment, according to the usual practice.~In addition to the systemic treatment, patients randomized into this experimental group will receive a SBRT of 45Gy in 3 fractions for hepatic and pulmonary metastasis, 27Gy in 3 fractions for bone metastasis and 33 Gy in 3 fractions for intra-cranial metastasis.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Systemic treatment
Description: According to the usual practice, patients will receive their systemic treatment, composed of :~* Taxane + trastuzumab +pertuzumab for metastatic breast cancers;~* FOLFOX or FOLFIRI + cetuximab for metastatic colorectal cancers;~* 5FU-Platine + cetuximab for metastatic head and neck cancers; for six cycles and a maintenance of the targeted therapy until progression or unacceptable toxicity.~If progression occurs before the 6th cycles, patients could receive a different line of treatment, according to the usual practice.
Study: NCT04652219

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: gucy2c cart cells
Description: Patients with advanced malignant gastrointestinal tumors were injected with CART cells
Study: NCT01678404

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 131I-rituximab
Study: NCT01154257

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cleaning of teeth with a toothbrush
Description: This is a split mouth study where patients will have one side of their mouth randomised for teeth cleaning with a toothbrush. Cleaning will be twice daily from recruitment until day seven.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cleaning of teeth with a foam swab
Description: This is a split mouth study where patients will have one side of their mouth randomised for teeth cleaning with a foam swab. Cleaning will be twice daily from recruitment until day seven.
Study: NCT04527770

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Ultrasound guided median nerve hydrodiseection using dexamethasone or midazolam

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam injection
Description: intracarpal injection of midazolam and bupivacaine 0.5%
Study: NCT00067730

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drotrecogin Alfa (activated)